Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(0.25)
# 4,623
Out of 5,099 analysts
146
Total ratings
31.9%
Success rate
-8.8%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $86 | $57.44 | +49.72% | 21 | Nov 3, 2026 | |
| VNDA Vanda Pharmaceuticals | Reiterated: Buy | $11 | $3.88 | +183.51% | 7 | Oct 28, 2026 | |
| UTHR United Therapeutics | Reiterated: Buy | $700 → $850 | $596.13 | +42.59% | 6 | Oct 26, 2026 | |
| ENSC Ensysce Biosciences | Initiated Coverage: Buy | $2 | $0.3821 | +423.42% | 1 | Oct 20, 2026 | |
| BRVE Braveheart Bio | Reiterated: Buy | $40 | $21.04 | +90.11% | 2 | Oct 19, 2026 | |
| MNKD MannKind | Reiterated: Buy | $8 | $3.65 | +119.18% | 7 | Oct 19, 2026 | |
| OMER Omeros | Reiterated: Buy | $22 | $17.83 | +23.39% | 3 | Oct 14, 2026 | |
| CTMX CytomX Therapeutics | Reiterated: Buy | $12 | $2.23 | +438.12% | 6 | Oct 13, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Hold | $400 → $325 | $158.00 | +105.70% | 12 | Sep 30, 2026 | |
| TENX Tenax Therapeutics | Reiterated: Buy | $35 | $1.80 | +1,844.44% | 4 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $3 | $0.7211 | +316.03% | 1 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $33.55 | +108.64% | 1 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $235 | $109.31 | +114.98% | 5 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.7771 | +414.73% | 1 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $1.54 | +159.74% | 2 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $11.52 | +334.03% | 1 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $9.45 | - | 6 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $480 | $553.15 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $405 → $340 | $465.45 | n/a | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $52 → $55 | $63.02 | n/a | 8 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $70 → $80 | $170.33 | n/a | 8 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $795 → $925 | $961.26 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $10 | $16.14 | n/a | 6 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $49.99 | n/a | 3 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $3.05 | n/a | 4 | Mar 20, 2023 |
BioMarin Pharmaceutical
Nov 3, 2026
Maintained: Buy
Price Target: $86
Current: $57.44
Upside: +49.72%
Vanda Pharmaceuticals
Oct 28, 2026
Reiterated: Buy
Price Target: $11
Current: $3.88
Upside: +183.51%
United Therapeutics
Oct 26, 2026
Reiterated: Buy
Price Target: $700 → $850
Current: $596.13
Upside: +42.59%
Ensysce Biosciences
Oct 20, 2026
Initiated Coverage: Buy
Price Target: $2
Current: $0.3821
Upside: +423.42%
Braveheart Bio
Oct 19, 2026
Reiterated: Buy
Price Target: $40
Current: $21.04
Upside: +90.11%
MannKind
Oct 19, 2026
Reiterated: Buy
Price Target: $8
Current: $3.65
Upside: +119.18%
Omeros
Oct 14, 2026
Reiterated: Buy
Price Target: $22
Current: $17.83
Upside: +23.39%
CytomX Therapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $12
Current: $2.23
Upside: +438.12%
Alnylam Pharmaceuticals
Sep 30, 2026
Reiterated: Hold
Price Target: $400 → $325
Current: $158.00
Upside: +105.70%
Tenax Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $35
Current: $1.80
Upside: +1,844.44%
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $3
Current: $0.7211
Upside: +316.03%
Aug 17, 2026
Reiterated: Buy
Price Target: $70
Current: $33.55
Upside: +108.64%
Aug 6, 2026
Reiterated: Buy
Price Target: $235
Current: $109.31
Upside: +114.98%
May 21, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $0.7771
Upside: +414.73%
May 18, 2026
Reiterated: Buy
Price Target: $4
Current: $1.54
Upside: +159.74%
Apr 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $11.52
Upside: +334.03%
Mar 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $9.45
Upside: -
Feb 11, 2025
Reiterated: Buy
Price Target: $480
Current: $553.15
Upside: n/a
Feb 5, 2025
Reiterated: Buy
Price Target: $405 → $340
Current: $465.45
Upside: n/a
Feb 4, 2025
Reiterated: Hold
Price Target: $52 → $55
Current: $63.02
Upside: n/a
Nov 6, 2024
Reiterated: Hold
Price Target: $70 → $80
Current: $170.33
Upside: n/a
Apr 17, 2024
Reiterated: Hold
Price Target: $795 → $925
Current: $961.26
Upside: n/a
Feb 23, 2024
Reiterated: Buy
Price Target: $15 → $10
Current: $16.14
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $49.99
Upside: n/a
Mar 20, 2023
Reiterated: Hold
Price Target: $3
Current: $3.05
Upside: n/a